PA
CLDX icon

Perceptive Advisors’s Celldex Therapeutics CLDX Stock Holding History

Perceptive Advisors’s Portfolio CLDX Stock Details CLDX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2013
Q4 		– Sell
-3,220
Closed -$1.71M – 116
2013
Q3 		$1.71M Buy
+3,220
New +$1.1M 0.14% 64

Other funds holding CLDX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return
EAM
Eventide Asset Management Boston, Massachusetts $6.05B AUM 76.64% 1-Year Est. Return

Perceptive Advisors's CLDX Position: Q1 2022 in Review

Perceptive Advisors sold out of Celldex Therapeutics (CLDX) in Q1 2022, closing a stake of 229,807 shares — an estimated $8.88M sold.

Perceptive Advisors first reported a position in CLDX in Q4 2014 and held it in 7 quarters. The position peaked at $24.8M in Q2 2021. 168 funds tracked by Wall St. Rank hold CLDX as of Q1 2022.

  • Perceptive Advisors reported no remaining Celldex Therapeutics position as of Q1 2022 after selling out during the quarter.
  • Perceptive Advisors sold 229,807 Celldex Therapeutics shares in Q1 2022, an estimated $8.88M.
  • Perceptive Advisors first reported a position in Celldex Therapeutics in Q4 2014 and held it in 7 quarters.
  • Perceptive Advisors's Celldex Therapeutics position peaked at $24.8M in Q2 2021.
  • 168 funds tracked by Wall St. Rank held Celldex Therapeutics as of Q1 2022.

Based on Perceptive Advisors's 13F filing for Q1 2022, filed 16 May 2022.